PE20130317A1 - Derivados de amino-tropano - Google Patents
Derivados de amino-tropanoInfo
- Publication number
- PE20130317A1 PE20130317A1 PE2012002444A PE2012002444A PE20130317A1 PE 20130317 A1 PE20130317 A1 PE 20130317A1 PE 2012002444 A PE2012002444 A PE 2012002444A PE 2012002444 A PE2012002444 A PE 2012002444A PE 20130317 A1 PE20130317 A1 PE 20130317A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- aza
- benzamide
- bicycle
- trifluoromethyl
- Prior art date
Links
- FHPZUVVXVRYZAS-SFYZADRCSA-N (1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-5-amine Chemical class C1CC[C@@]2(N)CC[C@]1([H])N2C FHPZUVVXVRYZAS-SFYZADRCSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 2
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE AMINO-TROPANO DE FORMULA (I) DONDE R1, R2 Y R3 SON CADA UNO H, ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALCOXI INFERIOR, CICLOALQUILO O S-ALQUILO INFERIOR. SON COMPUESTOS PREFERIDOS: 2-METOXI-N-((1S,2S,5R)-8-METIL-2-FENIL-8-AZA-BICICLO[3.2.1]OCT-2-IL)-6-METILSULFANIL-4-TRIFLUOROMETIL-BENZAMIDA; 2-CICLOPROPIL-N-((1RS,2RS,5SR)-8-METIL-2-FENIL-8-AZA-BICICLO[3.2.1]OCT-2-IL)-4-TRIFLUOROMETIL-BENZAMIDA; 2-METOXI-6-METIL-N-((1RS,2RS,5SR)-8-METIL-2-FENIL-8-AZA-BICICLO[3.2.1]OCT-2-IL)-4-TRIFLUOROMETIL-BENZAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE GLICINA 1 (GlyT-1) SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, TRASTORNOS DE DEMENCIA, ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10166757 | 2010-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130317A1 true PE20130317A1 (es) | 2013-03-11 |
Family
ID=44310862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002444A PE20130317A1 (es) | 2010-06-22 | 2011-06-17 | Derivados de amino-tropano |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8153653B2 (es) |
| EP (1) | EP2585456B1 (es) |
| JP (1) | JP5546684B2 (es) |
| KR (1) | KR101445016B1 (es) |
| CN (1) | CN102947297B (es) |
| AR (1) | AR081961A1 (es) |
| AU (1) | AU2011269145A1 (es) |
| BR (1) | BR112012032576A2 (es) |
| CA (1) | CA2801458C (es) |
| CL (1) | CL2012003552A1 (es) |
| CO (1) | CO6630160A2 (es) |
| CR (1) | CR20120614A (es) |
| EA (1) | EA201291374A1 (es) |
| EC (1) | ECSP12012347A (es) |
| ES (1) | ES2550831T3 (es) |
| IL (1) | IL222998A0 (es) |
| MA (1) | MA34251B1 (es) |
| MX (1) | MX2012013820A (es) |
| PE (1) | PE20130317A1 (es) |
| PH (1) | PH12012502339A1 (es) |
| SG (1) | SG186329A1 (es) |
| TW (1) | TWI417097B (es) |
| WO (1) | WO2011161006A1 (es) |
| ZA (1) | ZA201209248B (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG99853A1 (en) * | 1996-02-22 | 2003-11-27 | Neurosearch As | Tropane-derivatives, their preparation and use |
| US5834484A (en) * | 1997-03-12 | 1998-11-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Cocaine analogs |
| CA2537292C (en) * | 2003-09-09 | 2013-04-02 | F. Hoffmann-La Roche Ag | 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| FR2861076B1 (fr) | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique |
| US7572792B2 (en) * | 2004-04-29 | 2009-08-11 | Merck & Co., Inc. | Azetidine glycine transporter inhibitors |
| FR2873693B1 (fr) * | 2004-07-29 | 2006-09-15 | Sanofi Synthelabo | Derives d'amino-tropane, leur preparation et leur application en therapeutique |
| GB0428231D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
| CA2593453A1 (en) * | 2005-01-06 | 2006-07-13 | F. Hoffmann-La Roche Ag | Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| TW200846328A (en) * | 2007-02-01 | 2008-12-01 | Glaxo Group Ltd | GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
| WO2010020548A1 (en) * | 2008-08-20 | 2010-02-25 | F. Hoffmann-La Roche Ag | Glyt1 receptor antagonists |
-
2011
- 2011-06-15 US US13/160,559 patent/US8153653B2/en not_active Expired - Fee Related
- 2011-06-17 PH PH1/2012/502339A patent/PH12012502339A1/en unknown
- 2011-06-17 JP JP2013515816A patent/JP5546684B2/ja not_active Expired - Fee Related
- 2011-06-17 MA MA35398A patent/MA34251B1/fr unknown
- 2011-06-17 SG SG2012091708A patent/SG186329A1/en unknown
- 2011-06-17 PE PE2012002444A patent/PE20130317A1/es not_active Application Discontinuation
- 2011-06-17 CA CA2801458A patent/CA2801458C/en not_active Expired - Fee Related
- 2011-06-17 EP EP11728224.4A patent/EP2585456B1/en active Active
- 2011-06-17 CN CN201180030703.3A patent/CN102947297B/zh not_active Expired - Fee Related
- 2011-06-17 BR BR112012032576A patent/BR112012032576A2/pt active Search and Examination
- 2011-06-17 MX MX2012013820A patent/MX2012013820A/es active IP Right Grant
- 2011-06-17 WO PCT/EP2011/060073 patent/WO2011161006A1/en not_active Ceased
- 2011-06-17 KR KR1020127033182A patent/KR101445016B1/ko not_active Expired - Fee Related
- 2011-06-17 ES ES11728224.4T patent/ES2550831T3/es active Active
- 2011-06-17 AU AU2011269145A patent/AU2011269145A1/en not_active Abandoned
- 2011-06-17 EA EA201291374A patent/EA201291374A1/ru unknown
- 2011-06-20 TW TW100121503A patent/TWI417097B/zh not_active IP Right Cessation
- 2011-06-21 AR ARP110102138A patent/AR081961A1/es unknown
-
2012
- 2012-10-26 CO CO12192372A patent/CO6630160A2/es active IP Right Grant
- 2012-11-12 IL IL222998A patent/IL222998A0/en unknown
- 2012-12-05 CR CR20120614A patent/CR20120614A/es unknown
- 2012-12-06 ZA ZA2012/09248A patent/ZA201209248B/en unknown
- 2012-12-17 CL CL2012003552A patent/CL2012003552A1/es unknown
- 2012-12-20 EC ECSP12012347 patent/ECSP12012347A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG186329A1 (en) | 2013-01-30 |
| EP2585456A1 (en) | 2013-05-01 |
| AR081961A1 (es) | 2012-10-31 |
| CN102947297A (zh) | 2013-02-27 |
| CR20120614A (es) | 2013-01-11 |
| EA201291374A1 (ru) | 2013-06-28 |
| EP2585456B1 (en) | 2015-09-16 |
| BR112012032576A2 (pt) | 2016-11-22 |
| HK1179606A1 (zh) | 2013-10-04 |
| MA34251B1 (fr) | 2013-05-02 |
| ECSP12012347A (es) | 2013-01-31 |
| PH12012502339A1 (en) | 2013-02-11 |
| CN102947297B (zh) | 2015-12-16 |
| ES2550831T3 (es) | 2015-11-12 |
| US8153653B2 (en) | 2012-04-10 |
| WO2011161006A1 (en) | 2011-12-29 |
| AU2011269145A1 (en) | 2012-11-08 |
| KR101445016B1 (ko) | 2014-09-26 |
| KR20130029414A (ko) | 2013-03-22 |
| ZA201209248B (en) | 2013-08-28 |
| TWI417097B (zh) | 2013-12-01 |
| CA2801458C (en) | 2018-10-30 |
| JP2013529607A (ja) | 2013-07-22 |
| TW201206438A (en) | 2012-02-16 |
| MX2012013820A (es) | 2013-01-28 |
| IL222998A0 (en) | 2013-02-03 |
| CL2012003552A1 (es) | 2013-04-12 |
| US20110312993A1 (en) | 2011-12-22 |
| CA2801458A1 (en) | 2011-12-29 |
| CO6630160A2 (es) | 2013-03-01 |
| JP5546684B2 (ja) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142376A1 (es) | Fluormetil-5,6-dihidro-4h-[1,3]oxazinas | |
| NI201200089A (es) | INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA. | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| PE20141205A1 (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
| PE20170464A1 (es) | Terapia de combinacion de alzheimer usando un anticuerpo monoclonal abeta anti-n3pglu mas un inhibidor de bace | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| CL2010001159A1 (es) | Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. | |
| MX2014002113A (es) | Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso. | |
| MX349556B (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
| PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
| IN2014DN03206A (es) | ||
| UY33694A (es) | ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?. | |
| UY32391A (es) | Compuestos amino-heterocíclicos | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| PE20141280A1 (es) | Inhibidores de aplicacion viral | |
| CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| NI201300111A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| CL2013003484A1 (es) | Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras. | |
| PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| UY29301A1 (es) | Derivados amida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |